In addition, the genetic (small interfering ribonucleic acid [siRNA]) and pharmacological (glyburide) inhibition of the NLRP3 inflammasome in CFs can block this signaling pathway. The gene discussed is NLRP3; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.